All News
TNR: Early RA - Referrals and Treatment
This Tuesday Night Rheumatology was an hour long panel discussion featuring Drs. Jack Cush, Vivian Bykerk, Glen Hazelwood and Martin J. Bergman.
The Panel discussed Rheumatologists views on Early RA referral and intake, initial treatment preferences and views on diagnosing and treating pre-clinical RA.
Hydroxychloroquine Adherence Lowers Cardiovascular Risks
Daily hydroxychloroquine (HCQ) is better than an apple a day; as a new study shows that adherence to the antimalarial agent significantly lowers future risk of cardiovascular events in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) patients.
Read Article
RheumNow Podcast – with Special Guest Dr. Janet Pope (9.8.2023)
This week, Dr. Jack Cush reviews the news with special guest, Dr. Janet Pope. They discuss "Not-non-Inferior", large scale genetic screening, Zoster risk w/ newer lupus drugs, tapering, RA referral problems and the TNR webinar session on "ORAL Surveillance Revisited".
Read Article
Hard Decisions in RA (9.1.2023)
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow, and introduces our September campaign - "Hard Decisions in RA".
Read Article
SGLT2 Inhibitors as Gout Treatment
Patients with gout and type 2 diabetes treated with SGLT2 inhibitors not only had reduced numbers of gout flares, but also lived longer compared with other such patients receiving other medications, researchers said.
Read Article
Hip Replacement Surgery After Age 90
Potentially modifiable comorbid conditions and complications have a major impact on the risks of total hip arthroplasty (THA) for people in their nineties, reports a study in The Journal of Bone & Joint Surgery.
Read Article
Before You Know It (8.25.2023)
Dr. Jack Cush comments on the news and journal articles from the past week on RheumNow.com: VEXAS scoring, scleroderma sine scleroderma and head scratchers from southeast Asia.
Read Article
Biologic Adherence and Drug Survival in RA Patients
A real-world rheumatoid arthritis (RA) cohort study from Israel shows significant variability of drug survival using biologic disease-modifying anti-rheumatics drugs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs).
Read Article
Fracture Risk Quantified for Older Spondyloarthritis Patients
Medicare beneficiaries with ankylosing spondylitis (AS) incur frequent bone fractures, a new study indicated, with the risk boosted by some unsurprising factors but also including one that was not expected.
Read Article
Mono- and Oligo- are Different (8.18.2023)
Dr. Jack Cush reviews the news and journal reports from RheumNow.com this past week.
Read Article
COSMOS: Guselkumab's Immunologic Benefits in Psoriatic Arthritis
The IL-23 inhibitor guselkumab was studied in active psoriatic arthritis patients in the phase 3b COSMOS trial, and shown to be clinically effective while reducing multiple effector cytokines, including those associated with the IL-23/IL-17 pathway.
Read Article
Stable Safety Outcomes with Abatacept
The safety of abatacept was studied using patients with rheumatoid arthritis (RA) from 7 European registers, revealing safety signals on par with that previously reported with no new safety concerns.
Read Article
The Adalimumab Biosimilar Glut
In 2023, three marketed biosimilars (Actemra, Stelara, Humira) had their patents expire, opening opportunities for multiple new biosimilars; but with competition comes a word salad of new drug names, confusion and nonsensical discounts.
Read Article
Glucocorticoid Affects Weight, but not Blood Pressure in RA
A pooled analysis of 5 randomized controlled trials (RCTs) shows that the effects of 2 years of low-dose glucocorticoid (GC) treatment in rheumatoid arthritis (RA) can significantly increase increase body weight, but not blood pressure.
Read Article
Colchicine or Prednisone in CPPD?
The COLCHICORT trial in patients with acute calcium pyrophosphate crystal arthritis (CPPD) demonstrated equivalent efficacy for both colchicine and prednisone, yet different safety signals were seen.
Read Article
Steroid Tapering Called Safe in Older RA Patients
Most rheumatoid arthritis (RA) patients 65 and older who had 5 mg/day of prednisolone added to standard care were successfully weaned from the steroid without seeing substantial increases in disease activity, researchers said.
Read Article
Links:
Links:
Links:
Links:
